Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Drug

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

Fineline Cube Apr 29, 2026
Company Drug

Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment

Fineline Cube Nov 28, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...

Company Drug

MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study

Fineline Cube Nov 28, 2024

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III...

Policy / Regulatory

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs

Fineline Cube Nov 28, 2024

The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...

Company Deals

Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs

Fineline Cube Nov 28, 2024

Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...

Policy / Regulatory

China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030

Fineline Cube Nov 28, 2024

The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...

Company Drug

Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303

Fineline Cube Nov 28, 2024

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...

Policy / Regulatory

NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs

Fineline Cube Nov 28, 2024

The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...

Company Drug

BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments

Fineline Cube Nov 28, 2024

China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders

Fineline Cube Nov 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE

Fineline Cube Nov 28, 2024

Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...

Company Drug

Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment

Fineline Cube Nov 28, 2024

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...

Company Drug

China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005

Fineline Cube Nov 28, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...

Company Medical Device

Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA

Fineline Cube Nov 28, 2024

The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport...

Company Drug

GSK plc Receives EC Approval for Single-Vial Menveo Vaccine for Meningococcal Disease

Fineline Cube Nov 28, 2024

GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European...

Company Deals

TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China

Fineline Cube Nov 28, 2024

China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand...

Company Drug

Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA

Fineline Cube Nov 28, 2024

Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment

Fineline Cube Nov 28, 2024

China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...

Company Drug

Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer

Fineline Cube Nov 28, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...

Company

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore

Fineline Cube Nov 28, 2024

Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore....

Company Drug

Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment

Fineline Cube Nov 27, 2024

China-based Chia Tai Tianqing has announced that the National Medical Products Administration (NMPA) has granted...

Posts pagination

1 … 250 251 252 … 658

Recent updates

  • Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis
  • Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness
  • Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required
  • GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma
  • Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Company

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

Company Drug

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

Company Drug

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.